A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease

NCT07120152 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

439

Enrollment

OTHER

Sponsor class

Conditions

IBD - Inflammatory Bowel Disease
RA - Rheumatoid Arthritis

Interventions

DRUG: Subcutaneous infliximab CT-P13 Remsima®SC

Sponsor

Erwin Dreesen

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]